August 29, 2018
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Launch of new Anti-CD20 Antibodies
that can be used in combination with the anti-cancer agent TREAKISYM®

TOKYO, Japan, August 29, 2018 -- Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo) andNippon Shinyaku Co., Ltd. (Headquarters: Kyoto) announced today that GAZYVA® (non-proprietaryname: obinutuzumab) anti-CD20 antibodies(*) has been listed and launched in combination with theanti-cancer agent TREAKISYM® as a therapeutic option for CD20 positive follicular lymphoma.
https://www.chugai-pharm.co.jp/english/news/detail/20180829150001.html
SymBio Pharmaceuticals Limited (Headquarters: Tokyo, Japan; hereinafter referred to as "SymBio")obtained approval for a partial change to its marketing authorization for the anti-cancer agent
TREAKISYM® (non-proprietary name: bendamustine hydrochloride) on July 2, 2018. The launch ofGAZYVA® enables the combined use of TREAKISYM® and GAZYVA® for the treatment of CD20
positive follicular lymphoma, a typical histologic type of low-grade NHL, providing an additional
treatment option to patients as an alternative to conventional rituximab (BR therapy).
TREAKISYM® has been newly included as a standard-of-care option for low-grade B-cell
non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia in the Guidelines
for Tumors of Hematopoietic and Lymphoid Tissues 2018 issued by JSH (Japan Society ofHematology) on July 20, 2018.
SymBio is conducting Phase 3 clinical study of TREAKISYM® in relapsed refractory diffuse large
B-cell lymphoma and shall continue to develop its business to enhance corporate value by further
strengthening the position of TREAKISYM® as a standard therapy for the treatment of malignantlymphoma.

1(*) CD20 is a transmembrane phosphoprotein that is a surface-membrane molecule specifically
expressed on lymphocyte B cells. Anti-CD20 antibodies recognize and bind to CD20 in vivo, thereby
targeting B cells for destruction by natural killer cells.
[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About TREAKISYM®
TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug firstused in Germany in the 1970s, is now widely used in more than 50 countries with indications for
low-grade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.
TREAKISYM® Intravenous Infusion 100 mg was approved in October, 2010 for manufacturingand marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma
and mantle cell lymphoma in Japan.

TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia inJapan in August 2016.

TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product, was approved for
manufacturing and marketing in Japan in September 2016.

TREAKISYM® was approved for the additional indication of first-line treatment of low-grade
B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma in Japan in December 2016.

TREAKISYM® is currently under Phase 3 clinical study for indication of diffuse large B-celllymphoma and accumulating cases.

TREAKISYM® has been marketed by SymBio through its partnership with Eisai Co., Ltd. since
December 2010.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously
served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May
2016 SymBio incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc.
(Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio’s underlying
corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty
biopharmaceutical company dedicated to addressing underserved medical needs with maintherapeutic focus in oncology, hematology and pain management.

2